Literature DB >> 16797952

Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN.

Mohsen Tafaghodi1, Mahmood-Reza Jaafari, Sayyed Abolghasem Sajadi Tabassi.   

Abstract

To increase the systemic and mucosal immune responses against the nasally administered tetanus toxoid, liposomes as a drug delivery system and CpG-ODN as an adjuvant were evaluated. Rabbits were nasally immunized with entrapped tetanus toxoid (TT) and CpG-ODN in neutral liposomes and systemic and mucosal immune responses were determined. Liposomes containing TT and CpG-ODN were prepared by dehydration-rehydration method. The volume mean diameter of liposomes was 2.3+/-0.6 microm. Encapsulation efficiency of TT and CpG-ODN was determined as 54.0+/-8.8 and 60.1+/-7.4, respectively. The leakage of the encapsulated TT from liposomes reached 7.38% after 3 months. Encapsulated TT kept its intact structure, and its immunoreactivity was also completely preserved, as shown by SDS-PAGE and ELISA methods. The highest serum IgG and antitoxin titers were observed in groups immunized with solution formulations (P < 0.001). However the highest mucosal sIgA titers were achieved by liposomes encapsulated with TT. CpG-ODN as an adjuvant was able to increase the serum IgG and antitoxin titers when co-administered with TT solution (P < 0.05) or co-encapsulated with TT in liposomes (P < 0.01), but failed to increase the sIgA titers in nasal lavages. No hemolysis occurred on incubation of liposomes and human RBCs. Also after nasal administration of plain liposomes to human volunteers, no local irritation was seen. Intranasal administration of liposomes encapsulated with vaccines showed to be an effective way for inducing the mucosal immune responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797952     DOI: 10.1016/j.ejpb.2006.05.005

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

1.  New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model.

Authors:  Nundia Louis; Sharon Liu; Xingyao He; Daryl C Drummond; Charles O Noble; Stewart Goldman; Sabine Mueller; Krystof Bankiewicz; Nalin Gupta; Rintaro Hashizume
Journal:  J Neurooncol       Date:  2017-11-23       Impact factor: 4.130

2.  Materials innovation for co-delivery of diverse therapeutic cargos.

Authors:  Megan E Godsey; Smruthi Suryaprakash; Kam W Leong
Journal:  RSC Adv       Date:  2013-12-21       Impact factor: 3.361

3.  Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity.

Authors:  Béatrice Heurtault; Philippe Gentine; Jean-Sébastien Thomann; Corinne Baehr; Benoît Frisch; Françoise Pons
Journal:  Pharm Res       Date:  2008-09-10       Impact factor: 4.200

4.  Mucosal Adjuvant Potential of Quillaja saponins and Cross-linked Dextran Microspheres, Co-administered with Liposomes Encapsulated with Tetanus Toxoid.

Authors:  Faezeh Moghadam Ariaee; Mohsen Tafaghodi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

5.  Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (ALM) and Quillaja Saponins.

Authors:  Mohsen Tafaghodi; Maryam Eskandari; Ali Khamesipour; Mahmoud Reza Jaafari
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

Review 6.  Needle-Free Immunization with Chitosan-Based Systems.

Authors:  Bijay Singh; Sushila Maharjan; Princy Sindurakar; Ki-Hyun Cho; Yun-Jaie Choi; Chong-Su Cho
Journal:  Int J Mol Sci       Date:  2018-11-19       Impact factor: 5.923

7.  Liposomes as Adjuvants and Vaccine Delivery Systems.

Authors:  D S Tretiakova; E L Vodovozova
Journal:  Biochem (Mosc) Suppl Ser A Membr Cell Biol       Date:  2022-02-14

8.  The mucosal adjuvant potential of cross-linked dextran microspheres as dry powder.

Authors:  Mohsen Tafaghodi; Maryam Eskandari
Journal:  Iran J Basic Med Sci       Date:  2012-05       Impact factor: 2.699

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.